[{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"LG Chem","amount2":0.34999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"LG Chem \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"AVA6000","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LR19023","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"LG203003","moa":"DGAT2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tigulixostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tivozanib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Approved","graph3":"LG Chem","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Capsule","sponsorNew":"LG Chem \/ LG Chem","highestDevelopmentStatusID":"12","companyTruncated":"LG Chem \/ LG Chem"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Tigulixostat","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Innovent Biologics"},{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"LG Chem","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"LG Chem \/ UNICEF","highestDevelopmentStatusID":"12","companyTruncated":"LG Chem \/ UNICEF"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LB54640","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.31,"dosageForm":"","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LB-LR1109","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ AVEO Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ AVEO Oncology"},{"orgOrder":0,"company":"LG Chem","sponsor":"Yifan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"LG Chem \/ Yifan Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"LG Chem \/ Yifan Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by LG Chem

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Hyruan One (hyaluronic acid) is a small molecule, dihydrofolate reductase inhibitor, given intra-articularly. It is China’s first single-injection osteoarthritis treatment.

                          Brand Name : Hyruan One

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 03, 2024

                          Lead Product(s) : Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Yifan Pharmaceutical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : LB-LR1109, an anti-cancer investigational drug, works by modulationg LILRB1, it is being investigated in unresectable and metastatic non-small cell lung cancer, renal cell carcinoma, etc.

                          Brand Name : LB-LR1109

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 13, 2024

                          Lead Product(s) : LB-LR1109

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Aveo Oncology

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 trials for patients with acquired hypothalamic obesity.

                          Brand Name : LB54640

                          Molecule Type : Small molecule

                          Upfront Cash : $100.0 million

                          January 04, 2024

                          Lead Product(s) : LB54640

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Rhythm Pharmaceuticals

                          Deal Size : $305.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, LG Chem will supply UNICEF with its polio vaccine Eupolio and a pentavalent vaccine Eupenta that prevents diphtheria, pertussis, tetanus, hepatitis B and meningitis to solve global public health issues.

                          Brand Name : Eupolio

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 14, 2023

                          Lead Product(s) : Sabin Inactivated Polio Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : UNICEF

                          Deal Size : $200.0 million

                          Deal Type : Agreement

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.

                          Brand Name : LC350189

                          Molecule Type : Small molecule

                          Upfront Cash : $10.0 million

                          December 14, 2022

                          Lead Product(s) : Tigulixostat

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase III

                          Sponsor : Innovent Biologics

                          Deal Size : $95.5 million

                          Deal Type : Collaboration

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : AVEO will establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA® (tivozanib), which received U.S. FDA approval for the treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior s...

                          Brand Name : Fotivda

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 18, 2022

                          Lead Product(s) : Tivozanib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Aveo Oncology

                          Deal Size : $566.0 million

                          Deal Type : Acquisition

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...

                          Brand Name : LC350189

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 03, 2022

                          Lead Product(s) : Tigulixostat

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.

                          Brand Name : LG203003

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 14, 2022

                          Lead Product(s) : LG203003

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeuti...

                          Brand Name : LR19023

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 12, 2022

                          Lead Product(s) : LR19023

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : MaxCyte

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor (PD-L1 XT) with Affimer XT™ serum half-life extension for a range of indications.

                          Brand Name : PD-L1 XT

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 30, 2022

                          Lead Product(s) : PD-L1 XT

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Avacta Group

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank